Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Vestibular Schwannoma

Inclusion Criteria: * Male or female patients of \>= 18 years of age. * Patients with a documented diagnosis of unilateral or bilateral VS based on MRI and who have evidence of progressive vestibular schwannomas, and are considered poor candidates for surgery and radiation therapy or declined these treatments. * Patients must have a Karnofsky performance status \>=60% (or the equivalent ECOG level of 0-2) (see Appendix A; Performance Status Evaluation) and an expected survival of \>= three months. * No chemotherapy for two weeks prior to treatment under this research protocol and no external beam radiation for two weeks prior to treatment under this research protocol. * Patients must have adequate hematologic reserve with WBC\>=3000/mm3, absolute neutrophils \>=1500/mm3 and platelets \>=100,000/ mm3. Patients who are on Coumadin must have a platelet count of \>=150,000/ mm3. * Pre-enrollment chemistry parameters must show: bilirubin\< 1.5X the institutional upper limit of normal (IUNL); AST or ALT\< 2.5X IUNL and creatinine \< 1.5X IUNL. * Pre-enrollment coagulation parameters (PT and PTT) must be \<1.5X the IUNL. * Patients must agree to use a medically effective method of contraception during and for a period of three months after the treatment period. A pregnancy test will be performed on each premenopausal female of childbearing potential immediately prior to entry into the research study. Exclusion Criteria: * Previous treatment with Avastin®. * Women who are pregnant…